NO20082386L - Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav - Google Patents

Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav

Info

Publication number
NO20082386L
NO20082386L NO20082386A NO20082386A NO20082386L NO 20082386 L NO20082386 L NO 20082386L NO 20082386 A NO20082386 A NO 20082386A NO 20082386 A NO20082386 A NO 20082386A NO 20082386 L NO20082386 L NO 20082386L
Authority
NO
Norway
Prior art keywords
ligands
egfr
vegf
methods
binding specificity
Prior art date
Application number
NO20082386A
Other languages
English (en)
Norwegian (no)
Inventor
Haiqun Liu
Steve Holmes
Laurent S Jespers
Rudolf M T De Wildt
Armin Sepp
Olga Ignatovich
Roland Beckmann
Michael Steward
Malgorzata Pupecka
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20082386L publication Critical patent/NO20082386L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20082386A 2005-12-06 2008-05-26 Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav NO20082386L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (1)

Publication Number Publication Date
NO20082386L true NO20082386L (no) 2008-08-27

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082386A NO20082386L (no) 2005-12-06 2008-05-26 Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav

Country Status (13)

Country Link
US (2) US20100056439A1 (de)
EP (1) EP1966242A1 (de)
JP (1) JP2009518024A (de)
KR (1) KR20080077261A (de)
AU (1) AU2006323412A1 (de)
BR (1) BRPI0619463A2 (de)
CA (1) CA2632417A1 (de)
CR (1) CR10024A (de)
EA (1) EA013878B1 (de)
MA (1) MA30021B1 (de)
NO (1) NO20082386L (de)
TW (1) TW200804425A (de)
WO (1) WO2007066106A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2190861A4 (de) 2007-08-22 2011-03-30 Univ California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
TW200944231A (en) * 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
EP2220115A2 (de) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptide, variable antikörperdomänen und antagonisten
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
EP2259802A1 (de) * 2008-03-31 2010-12-15 Glaxo Group Limited Arzneimittelfusionen und konjugate
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2346526A2 (de) * 2008-09-22 2011-07-27 Massachusetts Institute of Technology Zusammensetzungen und verfahren zur verwendung von liganden-dimeren
WO2010046337A2 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for dc-sign
CA2744055A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
EP3543256A1 (de) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
MX2011008799A (es) * 2009-02-19 2011-09-27 Glaxo Group Ltd Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
EP2531523A1 (de) 2010-02-05 2012-12-12 Ablynx N.V. An serumalbumin bindende peptide und verbindungen, konstrukte und polypeptide damit
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
CA2808683A1 (en) * 2010-08-20 2012-02-23 Glaxosmithkline Intellectual Property Development Limited Improved anti-serum albumin binding variants
MX2013005847A (es) * 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP2777707A1 (de) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Verfahren zur Behandlung von Gehirntumoren
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
US20160251440A1 (en) * 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
EP3247407A4 (de) 2015-01-21 2018-08-22 Inhibrx LP Nichtimmunogene einzeldomänenantikörper
EP3253790A4 (de) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetraspezifische, octamere bindemittel und antikörper gegen das clostridium-difficile-toxin a und -toxin b zur behandlung einer infektion mit c. difficile
JP6807606B2 (ja) 2015-07-16 2021-01-06 インヒブルクス インコーポレイテッド 多価及び多重特異性ｄｒ５結合融合タンパク質
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN111936516B (zh) 2018-03-19 2023-03-03 上海药明生物技术有限公司 新型抗egfr抗体多肽
MY204320A (en) 2019-03-29 2024-08-22 Mogam Inst Biomedical Res Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
WO2022047169A1 (en) * 2020-08-28 2022-03-03 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221001B1 (hu) * 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1558645B1 (de) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
PT1687338E (pt) * 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Also Published As

Publication number Publication date
MA30021B1 (fr) 2008-12-01
CR10024A (es) 2008-09-22
EP1966242A1 (de) 2008-09-10
JP2009518024A (ja) 2009-05-07
AU2006323412A1 (en) 2007-06-14
CA2632417A1 (en) 2007-06-14
BRPI0619463A2 (pt) 2013-01-08
WO2007066106A1 (en) 2007-06-14
EA200801172A1 (ru) 2008-12-30
US20130041136A1 (en) 2013-02-14
KR20080077261A (ko) 2008-08-21
US20100056439A1 (en) 2010-03-04
EA013878B1 (ru) 2010-08-30
TW200804425A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20082960L (no) Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
DE602006005475D1 (de) Katheter
NO20085422L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
EP2134854A4 (de) Behandlungsverfahren unter verwendung von egfr-antikörpern und src-inhibitoren und damit verbundene formulierungen
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
NO20085421L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
DK1951759T3 (da) Anti-EGFR-antistoffer
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
MX2009011234A (es) Anticuerpos contra la il-25.